Arginine Adjunctive Therapy in Active TuberculosisReport as inadecuate




Arginine Adjunctive Therapy in Active Tuberculosis - Download this document for free, or read online. Document in PDF available to download.

Tuberculosis Research and Treatment - Volume 2015 2015, Article ID 205016, 5 pages -

Research Article

Department of Infectious Disease, School of Medicine, Arak University of Medical Sciences, Arak 38159 34798, Iran

Tuberculosis and Pediatric Infectious Diseases Research Center, Arak University of Medical Sciences, Arak 38159 34798, Iran

School of Medicine, Arak University of Medical Sciences, Arak 38159 34798, Iran

Received 12 December 2014; Revised 21 January 2015; Accepted 21 January 2015

Academic Editor: T. Ottenhoff

Copyright © 2015 Aliasghar Farazi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Dietary supplementation has been used as a mechanism to augment the immune system. Adjunctive therapy with L-arginine has the potential to improve outcomes in active tuberculosis. Methods. In a randomized clinical trial 63 participants with smear-positive pulmonary tuberculosis in Markazi Province of Iran were given arginine or placebo for 4 weeks in addition to conventional chemotherapy. The final treatment success, sputum conversion, weight gain, and clinical symptoms after one and two months were considered as primary outcomes and secondary outcomes were ESR, CRP, and Hg. Data were collected and analyzed with SPSS software ver. 18. Results. Arginine supplementation reduced constitutional symptoms in patients with smear-positive TB at the end of the first month of treatment. Arginine treated patients had significantly increased BMI at the end of the first and second months of treatment and and a reduced CRP at the end of the first month of treatment versus placebo group. Conclusion. Arginine is useful as an adjunctive therapy in patients with active tuberculosis, in which the effects are more likely mediated by the increased production of nitric oxide and improved constitutional symptoms and weight gain. This trial is registered with Clinical Trials Registry of Iran: IRCT201211179855N2.





Author: Aliasghar Farazi, Omid Shafaat, Masoomeh Sofian, and Manijeh Kahbazi

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents